Offshore Public Offerings and Capital Markets:

Logistics, Consumer, Energy and Automotives Sectors:

• Companies: Hainan Drinda New Energy Technology (first dual A+H listing for China-based PV Cell Company); China International Marine Containers (B-shares into H-shares); China Resources Cement; Qianyuan Microgem (on-going); Shuangdeng Group (on-going); REFIRE Group; Ruichang International; Laopu Gold; Tiantu Capital; Bank of Qingdao; Holly Futures, and Haitong Securities (the largest HK IPO in 2012)
• Underwriters and Sponsors: Koradior; PRADA; Huadian Fuxin Energy; Baoxin Auto; Glencore International; Guangzhou Auto, and Metallurgical Corporation

TMT, Education and Real Estate:

• Companies: Taimei Medical Technology; Qunabox Group Limited; Folangsi; UBOX Online; Yeahka; Chanjet Information Technology; Greentown Service Group, and China Vanke Co., Ltd. (B-shares into H-shares)
• Underwriters and Sponsors: Shouhui Group; Shanghai Voicecomm Infotech; Fourth Paradigm; Huafang Group; GDS; Zero2IPO; Lushang Life Services; Zhongguancun Science-Tech Leasing; Chen Lin Education Group; FingerTango; Digital Hollywood; China Merchants Land, and CapitaMalls Asia Limited

Life Sciences, Medical and Healthcare:

• Companies: TransThera Sciences; TYK Medicines; Sunho Biologics; Akeso Biopharma; Yonghe Medical; Adlai Nortye (Nasdaq); Beauty Farm; Shanghai Bio-heart; Luzhu Biotech; Cryofocus Medtech; Sipai Health; 3D Medicines; Gaush Meditech; Jenscare Scientific; Rainmed; Gushengtang; Acotec Scientific; Keymed Biosciences; Jacobio Pharmaceuticals; Simcere Pharmaceutical; Honliv Healthcare; Hygeia Healthcare; Peijia Medical; Shanghai Kindly Medical Instruments; Pharmaron; Aesthetic Medical International (Nasdaq); Hua Medicine; Viva Biotech, and Microport Scientific
• Underwriters and Sponsors: Bayzed Health Group; Qyuns Therapeutics; Shanghai HeartCare Medical; Harmonicare Medical, and Livzon Pharmaceutical (B-shares into H-shares)

Mergers and Acquisitions:

• Tianhui Biotech in the US$75 million NewCo model investment with Oramed
• Acotec Scientific in its approximately US$520 million voluntary partial offer by Boston Scientific
• Viva Biotech in its US$387.3 million acquisition of Langhua Pharmaceutical and US$135.4 million share placement
• Nat-Ace Pharmaceutical in its US$35 million acquisition of approximately 52.79% equity interest in the HK-listed Perception Digital Holdings Limited from its then controlling shareholders by way of an unconditional, mandatory cash offer to acquire all the issued shares and cancel all outstanding options
• Geely Automobile in its acquisition of Volvo Group from Ford Group at US$1.8 billion
• Newbridge Capital in its sale of approximately 16.67% equity interest in Shenzhen Development Bank to Ping An Insurance at US$1.68 billion
• China International Marine Containers (CIMC), in connection with its wholly owned subsidiary CIMC Hong Kong, in its sale of 70% equity interest in CIMC-TianDa to Pteris Global Limited (Pteris). As consideration, Pteris would issue US$75 million new shares to CIMC Hong Kong for its reverse takeover and become a subsidiary of CIMC. This transaction was deemed a new listing of Pteris on the Singapore Exchange
• Tenwow International in its pre-IPO investments in several rounds of bidding and accepting offers from various pre-IPO investors immediately before its US$203 million IPO on the Main Board of the Hong Kong Stock Exchange

Compliance

Numerous transactions in the life sciences, medical and healthcare industries as well as other industries, including:

• Beauty Farm, Cryofocus Medtech, 3D Medicines, Rainmed, Jenscare, Keymed Biosciences, Honliv Healthcare, Peijia Medical, Akesobio, Pharmaron, Shanghai Kindly Medical Instruments, Viva Biotech, FingerTango, Haohai Biological Technology, LifeTech, PetroChina, Vanke, China International Marine Containers Group, Air China and many others